{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:51:20Z","timestamp":1787611880636,"version":"build-2736575974"},"reference-count":76,"publisher":"Hamad bin Khalifa University Press (HBKU Press)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"Introduction: Ceftriaxone, a third-generation cephalosporin, is frequently used for the treatment of various bacterial infections as a broad-spectrum antibiotic for many decades. Although ceftriaxone is a well-tolerated drug in most cases, it can lead to serious liver injury, which can be a real challenge to the treating physician. Given the potentially serious adverse effects that can vary from mild biochemical abnormalities to complete liver failure, we intend to assess the spectrum of liver injury based on biochemical criteria for patients treated with ceftriaxone for common bacterial infections in Qatar.Objectives: This study aimed to explore the incidence of ceftriaxone-induced liver injury at Hazm Mebaireek General Hospital, Qatar, and to evaluate the relationship of the ceftriaxone dose, if any, with liver dysfunction.Methods: This retrospective study included hospitalized adult patients treated with ceftriaxone at our hospital from January 2019 to December 2019 and analyzed demographic and clinical data obtained from electronic medical records. This study determined the incidence of liver injury (primary outcome) in patients treated with ceftriaxone (2 g\/day) for \u2265\u00a02 consecutive days by reviewing liver function test results until the day of discharge and at the first outpatient follow-up.<\/jats:p>\n \n Results: The final data analysis included a total of 634 patients admitted and treated with ceftriaxone from January 2019 to December\n 2019.In<\/jats:ext-link>\n the multivariate analysis with propensity score adjustment, ceftriaxone was independently associated with liver injury, especially when combined with other agents utilizing hepatic metabolism.Conclusions: Ceftriaxone was associated with a significantly higher incidence of liver injury (19.7%) when used along with other medications that are metabolized in the liver, as found in the present study compared with other similar studies (approximately 2.9%\u201313.9%). Furthermore, the incidence was too high to be ignored in clinical practice.\n <\/jats:p>","DOI":"10.5339\/qmj.2022.27","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:30:41Z","timestamp":1657801841000},"source":"Crossref","is-referenced-by-count":10,"title":["Ceftriaxone-induced hepatotoxicity in patients with common medical infections in Qatar: A retrospective study"],"prefix":"10.5339","volume":"2022","author":[{"given":"Manish","family":"Barman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Al Hariri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hamad Medical Corporation, Doha, Qatar E-mail: drbarman@yahoo.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Rahman Mustafa","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hamad Medical Corporation, Doha, Qatar E-mail: drbarman@yahoo.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseem","family":"Ambra","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hamad Medical Corporation, Doha, Qatar E-mail: drbarman@yahoo.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israa","family":"Amjed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hamad Medical Corporation, Doha, Qatar E-mail: drbarman@yahoo.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Eid Nazzal Alharafsheh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hamad Medical Corporation, Doha, Qatar E-mail: drbarman@yahoo.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.N.","family":"Illahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hamuda","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hamad Medical Corporation, Doha, Qatar E-mail: drbarman@yahoo.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamedali","family":"Gaafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3277","reference":[{"issue":"(2):","key":"CIT0001","series-title":"Semin Gastrointest Dis","first-page":"113\u201324","article-title":"Drug-induced cholestasis","volume":"12","year":"2001"},{"issue":"(4):","key":"CIT0002","series-title":"Hepatology","first-page":"1377\u201387","article-title":"Drug-induced cholestasis","volume":"53","year":"2011"},{"issue":"(8):","key":"CIT0003","series-title":"Clin Radiol","first-page":"670\u20138","article-title":"Chemotherapy-induced sclerosing cholangitis","volume":"61","year":"2006"},{"issue":"(2):","key":"CIT0004","series-title":"Hepatology","first-page":"615\u201320","article-title":"Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events","volume":"51","year":"2010"},{"issue":"(11):","key":"CIT0005","series-title":"Expert Opin Drug Metab Toxicol","first-page":"1415\u201327","article-title":"Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science","volume":"4","year":"2008"},{"issue":"45:","key":"CIT0006","series-title":"Annu Rev Pharmacol Toxicol","first-page":"177\u2013202","article-title":"The role of metabolic activation in drug-induced hepatotoxicity","volume":"2005"},{"issue":"(1):","key":"CIT0007","series-title":"Curr Opin Drug Discov Devel","first-page":"38\u201346","article-title":"Drug withdrawals and the lessons within","volume":"9","year":"2006"},{"issue":"(5):","key":"CIT0008","series-title":"Am J Gastroenterol","first-page":"878\u201398","article-title":"ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","year":"2021"},{"issue":"(2):","key":"CIT0009","series-title":"Hepatology","first-page":"451\u20135","article-title":"Incidence of drug-induced hepatic injuries: a French population-based study","volume":"36","year":"2002"},{"issue":"(2):","key":"CIT0010","series-title":"Gastroenterology","first-page":"512\u201321","article-title":"Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","year":"2005"},{"issue":"(2):","key":"CIT0011","series-title":"Hepatology","first-page":"679\u201386","article-title":"Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network","volume":"60","year":"2014"},{"key":"CIT0012","article-title":"Drug-induced liver injury: premarketing clinical evaluation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)"},{"issue":"Suppl 2:","key":"CIT0013","series-title":"J Viral Hepat","first-page":"42\u20137","article-title":"Viral induction of autoimmunity: mechanisms and examples in hepatology","volume":"4;","year":"1997;"},{"issue":"(4):","key":"CIT0014","series-title":"Drug Saf","first-page":"277\u201394","article-title":"Drug-induced liver injury","volume":"30","year":"2007;"},{"issue":"(2):","key":"CIT0015","series-title":"Semin Liver Dis","first-page":"205\u201314","article-title":"Drug-induced hepatic steatosis","volume":"34","year":"2014"},{"issue":"(6):","key":"CIT0016","series-title":"Hepatology","first-page":"2001\u20139","article-title":"Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex","volume":"49","year":"2009"},{"issue":"(6):","key":"CIT0017","series-title":"Hepatology","first-page":"2003\u20139","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals","volume":"47","year":"2008"},{"issue":"(4):","key":"CIT0018","series-title":"World J Hepatol","first-page":"160\u20138","article-title":"Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease","volume":"6","year":"2014"},{"issue":"(3):","key":"CIT0019","series-title":"Hepatol Res","first-page":"E79\u201388","article-title":"Natural history and outcomes in drug-induced autoimmune hepatitis","volume":"46","year":"2016"},{"issue":"(1):","key":"CIT0020","series-title":"Hepatology","first-page":"201\u20136","article-title":"Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection","volume":"31","year":"2000"},{"key":"CIT0021","article-title":"Chapter 27. Hepatotoxicity of antitubercular drugs"},{"issue":"(7):","key":"CIT0022","series-title":"Nat Genet","first-page":"816\u20139","article-title":"HLA-b*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","year":"2009"},{"issue":"(8):","key":"CIT0023","series-title":"Liver Int","first-page":"1266\u201370","article-title":"Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1\/ABCB11 mutations?","volume":"33","year":"2013"},{"issue":"(1):","key":"CIT0024","series-title":"Hepatology","first-page":"388\u201396","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"58","year":"2013"},{"issue":"(4):","key":"CIT0025","series-title":"Gastroenterology","first-page":"914\u201328","article-title":"Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives","volume":"146","year":"2014"},{"issue":"(4):","key":"CIT0026","series-title":"Hepatology","first-page":"1399\u2013408","article-title":"Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network","volume":"60","year":"2014"},{"issue":"(7):","key":"CIT0027","series-title":"Am J Gastroenterol","first-page":"958\u201365","article-title":"Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury","volume":"111","year":"2016"},{"issue":"(3):","key":"CIT0028","series-title":"Indian J Pharmacol","first-page":"193\u20134","article-title":"Biliary pseudolithiasis secondary to ceftriaxone therapy","volume":"42","year":"2010"},{"issue":"(11):","key":"CIT0029","series-title":"J Clin Epidemiol","first-page":"1323\u201330","article-title":"Causality assessment of adverse reactions to drugs\u2013I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","year":"1993"},{"issue":"(6)[Editor2];99:","key":"CIT0030","series-title":"Gastroenterology","first-page":"1772\u20138","article-title":"Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility","volume":"99","year":"1990;"},{"issue":"(4):","key":"CIT0031","series-title":"Turk J Pediatr","first-page":"404\u20137","article-title":"Biliary precipitation during ceftriaxone therapy: frequency and risk factors","volume":"49","year":"2007"},{"issue":"(2):","key":"CIT0032","series-title":"Nat Rev Drug Discov","first-page":"131\u201348","article-title":"Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models","volume":"19","year":"2020;"},{"issue":"(8):","key":"CIT0033","series-title":"Aliment Pharmacol Ther","first-page":"1187\u201395","article-title":"Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic","volume":"24","year":"2006"},{"issue":"(1):","key":"CIT0034","series-title":"Br J Clin Pharmacol","first-page":"71\u201380","article-title":"Acute and clinically relevant drug-induced liver injury: a population-based case-control study","volume":"58","year":"2004"},{"issue":"(3):","key":"CIT0035","series-title":"Curr Opin Gastroenterol","first-page":"222\u20136","article-title":"Drug-induced liver injury: a clinical update","volume":"26","year":"2010"},{"issue":"(7):","key":"CIT0036","series-title":"J Antimicrob Chemother","first-page":"1431\u201346","article-title":"Hepatic safety of antibiotics used in primary care","volume":"66","year":"2011"},{"issue":"11:","key":"CIT0037","series-title":"Infect Drug Resist","first-page":"1645\u201358","article-title":"Antibiotic resistance: a rundown of a global crisis","volume":"10;","year":"2018"},{"issue":"Suppl 2:","key":"CIT0038","series-title":"Clin Infect Dis","first-page":"S44\u20138","article-title":"Drug-induced liver injury","volume":"38;","year":"2004"},{"issue":"(2):","key":"CIT0001","series-title":"Semin Gastrointest Dis","first-page":"113\u201324","article-title":"Drug-induced cholestasis","volume":"12","year":"2001"},{"issue":"(4):","key":"CIT0002","series-title":"Hepatology","first-page":"1377\u201387","article-title":"Drug-induced cholestasis","volume":"53","year":"2011"},{"issue":"(8):","key":"CIT0003","series-title":"Clin Radiol","first-page":"670\u20138","article-title":"Chemotherapy-induced sclerosing cholangitis","volume":"61","year":"2006"},{"issue":"(2):","key":"CIT0004","series-title":"Hepatology","first-page":"615\u201320","article-title":"Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events","volume":"51","year":"2010"},{"issue":"(11):","key":"CIT0005","series-title":"Expert Opin Drug Metab Toxicol","first-page":"1415\u201327","article-title":"Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science","volume":"4","year":"2008"},{"issue":"45:","key":"CIT0006","series-title":"Annu Rev Pharmacol Toxicol","first-page":"177\u2013202","article-title":"The role of metabolic activation in drug-induced hepatotoxicity","volume":"2005"},{"issue":"(1):","key":"CIT0007","series-title":"Curr Opin Drug Discov Devel","first-page":"38\u201346","article-title":"Drug withdrawals and the lessons within","volume":"9","year":"2006"},{"issue":"(5):","key":"CIT0008","series-title":"Am J Gastroenterol","first-page":"878\u201398","article-title":"ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","year":"2021"},{"issue":"(2):","key":"CIT0009","series-title":"Hepatology","first-page":"451\u20135","article-title":"Incidence of drug-induced hepatic injuries: a French population-based study","volume":"36","year":"2002"},{"issue":"(2):","key":"CIT0010","series-title":"Gastroenterology","first-page":"512\u201321","article-title":"Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","year":"2005"},{"issue":"(2):","key":"CIT0011","series-title":"Hepatology","first-page":"679\u201386","article-title":"Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network","volume":"60","year":"2014"},{"key":"CIT0012","article-title":"Drug-induced liver injury: premarketing clinical evaluation U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)"},{"issue":"Suppl 2:","key":"CIT0013","series-title":"J Viral Hepat","first-page":"42\u20137","article-title":"Viral induction of autoimmunity: mechanisms and examples in hepatology","volume":"4;","year":"1997;"},{"issue":"(4):","key":"CIT0014","series-title":"Drug Saf","first-page":"277\u201394","article-title":"Drug-induced liver injury","volume":"30","year":"2007;"},{"issue":"(2):","key":"CIT0015","series-title":"Semin Liver Dis","first-page":"205\u201314","article-title":"Drug-induced hepatic steatosis","volume":"34","year":"2014"},{"issue":"(6):","key":"CIT0016","series-title":"Hepatology","first-page":"2001\u20139","article-title":"Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex","volume":"49","year":"2009"},{"issue":"(6):","key":"CIT0017","series-title":"Hepatology","first-page":"2003\u20139","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals","volume":"47","year":"2008"},{"issue":"(4):","key":"CIT0018","series-title":"World J Hepatol","first-page":"160\u20138","article-title":"Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease","volume":"6","year":"2014"},{"issue":"(3):","key":"CIT0019","series-title":"Hepatol Res","first-page":"E79\u201388","article-title":"Natural history and outcomes in drug-induced autoimmune hepatitis","volume":"46","year":"2016"},{"issue":"(1):","key":"CIT0020","series-title":"Hepatology","first-page":"201\u20136","article-title":"Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection","volume":"31","year":"2000"},{"key":"CIT0021","article-title":"Chapter 27. Hepatotoxicity of antitubercular drugs"},{"issue":"(7):","key":"CIT0022","series-title":"Nat Genet","first-page":"816\u20139","article-title":"HLA-b*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin","volume":"41","year":"2009"},{"issue":"(8):","key":"CIT0023","series-title":"Liver Int","first-page":"1266\u201370","article-title":"Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1\/ABCB11 mutations?","volume":"33","year":"2013"},{"issue":"(1):","key":"CIT0024","series-title":"Hepatology","first-page":"388\u201396","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"58","year":"2013"},{"issue":"(4):","key":"CIT0025","series-title":"Gastroenterology","first-page":"914\u201328","article-title":"Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives","volume":"146","year":"2014"},{"issue":"(4):","key":"CIT0026","series-title":"Hepatology","first-page":"1399\u2013408","article-title":"Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network","volume":"60","year":"2014"},{"issue":"(7):","key":"CIT0027","series-title":"Am J Gastroenterol","first-page":"958\u201365","article-title":"Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury","volume":"111","year":"2016"},{"issue":"(3):","key":"CIT0028","series-title":"Indian J Pharmacol","first-page":"193\u20134","article-title":"Biliary pseudolithiasis secondary to ceftriaxone therapy","volume":"42","year":"2010"},{"issue":"(11):","key":"CIT0029","series-title":"J Clin Epidemiol","first-page":"1323\u201330","article-title":"Causality assessment of adverse reactions to drugs\u2013I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","year":"1993"},{"issue":"(6)[Editor2];99:","key":"CIT0030","series-title":"Gastroenterology","first-page":"1772\u20138","article-title":"Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility","volume":"99","year":"1990;"},{"issue":"(4):","key":"CIT0031","series-title":"Turk J Pediatr","first-page":"404\u20137","article-title":"Biliary precipitation during ceftriaxone therapy: frequency and risk factors","volume":"49","year":"2007"},{"issue":"(2):","key":"CIT0032","series-title":"Nat Rev Drug Discov","first-page":"131\u201348","article-title":"Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models","volume":"19","year":"2020;"},{"issue":"(8):","key":"CIT0033","series-title":"Aliment Pharmacol Ther","first-page":"1187\u201395","article-title":"Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic","volume":"24","year":"2006"},{"issue":"(1):","key":"CIT0034","series-title":"Br J Clin Pharmacol","first-page":"71\u201380","article-title":"Acute and clinically relevant drug-induced liver injury: a population-based case-control study","volume":"58","year":"2004"},{"issue":"(3):","key":"CIT0035","series-title":"Curr Opin Gastroenterol","first-page":"222\u20136","article-title":"Drug-induced liver injury: a clinical update","volume":"26","year":"2010"},{"issue":"(7):","key":"CIT0036","series-title":"J Antimicrob Chemother","first-page":"1431\u201346","article-title":"Hepatic safety of antibiotics used in primary care","volume":"66","year":"2011"},{"issue":"11:","key":"CIT0037","series-title":"Infect Drug Resist","first-page":"1645\u201358","article-title":"Antibiotic resistance: a rundown of a global crisis","volume":"10;","year":"2018"},{"issue":"Suppl 2:","key":"CIT0038","series-title":"Clin Infect Dis","first-page":"S44\u20138","article-title":"Drug-induced liver injury","volume":"38;","year":"2004"}],"container-title":["Qatar Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2022\/3\/article-27.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2022\/3\/article-27.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2022\/3\/article-27.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:10:24Z","timestamp":1777309824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2022\/3\/article-27.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":76,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.5339\/qmj.2022.27","relation":{},"ISSN":["2227-0426"],"issn-type":[{"value":"2227-0426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}